Immunotherapy: New options in breast cancer treatment

Expert Review of Anticancer Therapy

Volumn 3, Issue 3, 2003, Pages 403-408

  Untch, Michael ^a   Ditsch, Nina ^a   Hermelink, Kerstin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Active specific immunotherapy; HER 2; Metastatic breast cancer; Passive immunotherapy; Theratope; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; LETROZOLE; M 77003; NAVELBINE; ONCOPROTEIN; PACLITAXEL; TAMOXIFEN; THERATOPE; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; NEUTROPENIA; ONCOGENE NEU; PASSIVE IMMUNIZATION; REVIEW; TREATMENT OUTCOME;

EID: 0037531577     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.3.403     Document Type: Review

References (23)

1. Morse MA. Technology evaluation: Theratope, Biomira, Inc. Curr. Opin. Mol. Ther. 2(4), 453-458 (2000).
2. Miles DW, Towlson KE, Graham R et al. A randomised Phase II study of sialyl-Tn and detox-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. J. Cancer 74, 1292 (1996).
3. Holmberg LA, Sandmaier BM. Theratope vaccine (STn-KLH). Exp. Opin. Biol. Ther. 1(5), 881-891 (2001).
4. Chazin VR, Kaledo M, Miller AD et al. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7(9), 1859-1866 (1992).
5. Pegram MD, Baly D, Wirth C. Antibody dependent cell-mediated cytotoxicity in breast cancer patients in Phase III clinical trials of humanized antiHER-2 antibody. Proc. Am. Assoc. Cancer Res. 38, 602 (1997).
6. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
7. Toikkanen S, Helin H, Isola J et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J. Clin. Oncol. 10, 1044-1048 (1992).
8. Buehler HJ, Kuter I, Richardson PG et al. Effective Her-2/neu diagnosis in breast cancer by a combination of immunohistochemistry and FISH. Proc. Am. Soc. Clin. Oncol. 19, 76a (2000) (Abstract 294).
9. Mass RD, Sanders C, Charlene K et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the herceptin pivotal trials. Proc. Am. Soc. Clin. Oncol. 19, 75a (1999) (Abstract 291).
10. Seidman AD, Fornire M, Esteva F et al. Final report: weekly herceptin and taxol for metastatic breast cancer (MBC): analysis of efficacy in Her-2/neu immunophenotype (IHC) and gene amplification (FISH). Proc. Am. Soc. Clin. Oncol. 19, 83a (2000) (Abstract 319).
11. Cobleigh A, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized antiHER-2 monoclonal antibody in women who have HER-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17(9), 2639-2648 (1999).
12. Vogel CL, Cobleigh MA, Tripathy D et al. First-line herceptin monotherapy in metastatic breast cancer. Oncology 61(Suppl. 2), 37-42 (2001).
13. Vogel CL, Cobleigh MA, Tripathy D et al. Superior outcomes with herceptin (trastuzumab) in fluorescence in situ hybridization (FISH)-selected patients. Proc. Am. Soc. Clin. Oncol. 24, 86 (2001).
14. Esteva FJ, Seidman AD, Fornier M et al. Analysis of response to weekly 1h taxol plus herceptin by immunophenotypic analysis in Her-2/neu overexpression (Her-2/neu +) and non-expressing (Her-2/neu-) metastatic breast cancer. Breast Cancer Res. Treat. 57, 29 (1999) (Abstract 17).
15. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N. Engl. J. Med. 344(11) 783-792 (2001).
16. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 19(10), 2722-2730 (2001).
17. Konecny G, Untch M, Crohns C et al. c-erbB-2: überexpression und herceptin® in der therapie des mammakarzinoms. In: Diagnostik und Therapie des Mammakarzinoms. W Zuckschwer, München, Germany (2000).
18. Borg A, Baldetorp B, Fernö M et al. ErbB-2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 81, 137-144 (1994).
19. Ravdin PM, Green S, Albain KS et al. Initial report of the SWOG Biological Correlative Study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF with tamoxifen (T) alone. Proc. Am. Soc. Clin. Oncol. 17, 97a (1998).
20. Mass R, Cobleigh M, Vogel C et al. Estrogen receptor status in the herceptin (trastuzumab) clinical trials: incidence and relation to clinical benefit. Proc. Am. Soc. Clin. Oncol. 24, 522 (2001).
21. Lipton A, Mouridsen H, Ali S et al. Serum Her-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. Proc. Am. Soc. Clin. Oncol. 24 (2001).
22. Konecny G, Pauletti G, Pegram M et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J. Natl Cancer Inst. 95, 142-153 (2003).
23. Burstein HJ, Harris LN, Gelman R et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing Stage II or III breast cancer a pilot study. J. Clin. Oncol. 21(1), 46-53 (2003).